{"id":"W3089120395","doi":"10.1016/j.annonc.2020.08.458","title":"356TiP A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Medicine; Chemotherapy; Olaparib; Oncology; Internal medicine; Metastatic breast cancer; Induction chemotherapy; Breast cancer; Cancer; Immunotherapy; Polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001007487,0.001267374,0.001923954,0.0002595173,0.0003350357,0.001108223,0.0006878761,0.00131896,0.01603092],"category_scores_gemma":[0.0009692587,0.0005271902,0.001551294,0.000264852,0.00077971,0.0009059544,0.000338132,0.003522856,0.002303504],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006752434,"about_ca_system_score_gemma":0.0009786395,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008065746,"about_ca_topic_score_gemma":0.002253179,"domain_scores_codex":[0.999606,0.0001911216,0.00002243752,0.00008376667,0.00002431963,0.00007245005],"domain_scores_gemma":[0.9995794,0.0001026445,0.00007579123,0.00003529789,0.00002476207,0.000182171],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9765672,0.005061833,0.0002949598,0.00034725,0.000603776,0.00001706466,0.00001934175,0.0002366516,0.002400748,0.000126477,0.001271215,0.01305361],"study_design_scores_gemma":[0.9555247,0.04151285,0.0009488714,0.00002239751,0.0003539309,0.00001676079,0.0000136245,0.0003578837,0.0002590053,0.0001480624,0.000832586,0.000009282956],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9733252,0.005715327,0.001178864,0.00194325,0.0015641,0.005206675,0.00388688,0.0002946374,0.006885091],"genre_scores_gemma":[0.976617,0.002560162,0.002611396,0.002465846,0.0005565611,0.004104781,0.003129228,0.00004761575,0.007907351],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01603092,"threshold_uncertainty_score":0.05362874,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09994990229484879,"score_gpt":0.4189594626512683,"score_spread":0.3190095603564195,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}